Cancer is an age-related malignant disease, and the discovery and use of biomarkers of cancer are of great value in helping cancer diagnosis and prognosis. Several molecular changes may occur during aging and the cancer process, of which DNA methylation is one. Currently, DNA methylation levels are assessed using methylation-based assay strategies as a molecular marker for cancer detection. The development of DNA methylation biomarkers in different cancer diseases will provide an important tool for cancer diagnosis and a valuable source for therapy development.
Fig.1 Interest of DNA methylation biomarker in cancer diagnosis. (Delpu Y, et al. 2013)
CD BioSciences is a biological services company that specializes in advanced DNA methylation technology. We offer DNA methylation biomarker discovery services for studying aging and its association with cancers.
Sample Requirements
At CD BioSciences, we emphasize the significance of meticulously curated samples to ensure the reliability and relevance of biomarker discovery. Our sample requirements encompass diverse cancer types, including kidney cancer, lung cancer, and breast cancer. Our service supports any biological tissue/cell samples used for DNA methylation analysis, commonly blood, saliva, urine, etc.
| Sample types |
Quantity |
Requirements |
| Blood samples |
> 3 ml |
EDTA anticoagulation tube collection, invert, and mix. |
| Saliva samples |
> 2 ml |
Use commercial saliva collection kits. |
| Urine samples |
> 3 ml |
Use commercial urine collection kits. |
| Other samples |
- |
Just follow the general sample collection conditions. |
Our DNA Methylation Biomarker Discovery Services for Aging-Related Cancers
- Discovery/validation of DNA methylation biomarkers of candidate sequences
CD BioSciences offers a systematic approach to discovering and validating DNA methylation biomarkers of candidate sequences associated with various aging-related cancers. Leveraging advanced high-throughput platforms, we conduct DNA methylation profiling to identify differential methylation patterns.
We identify differentially methylated regions (DMRs) or individual CpG sites that are significantly associated with aging and cancer. We then select candidate sequence DNA methylation biomarkers that show consistent and significant associations with aging and cancer. Our services consider markers that exhibit large effect sizes and reproducibility across independent datasets.
- DNA methylation biomarker analysis evaluation
We validate the selected candidate biomarkers to confirm the association between DNA methylation patterns and aging and cancer status. We assess their sensitivity, specificity, and predictive accuracy in distinguishing between different age groups or cancer stages.
Our Advantages
- We use advanced DNA methylation analysis techniques to establish standardized methods that can advance the discovery of DNA methylation biomarkers for studying aging and its association with cancers.
- We employ advanced statistical methods, machine learning algorithms, and custom-built pipelines to process and interpret complex DNA methylation data. Our comprehensive analysis allows us to identify and prioritize the promising candidate biomarkers associated with aging and cancer.
- We maintain stringent quality control measures at every step of the biomarker discovery and validation process. From sample handling and processing to data analysis and interpretation, we adhere to rigorous quality standards to ensure the accuracy and reliability of our results.
CD BioSciences has delivered many development projects for global customers with satisfactory feedback. Based on the experience of these projects and our proven technology platform, we are committed to helping our customers build and accelerate your DNA methylation research program to achieve your goals for DNA methylation applications in the cancer field. Please contact us to learn more.
References
- Mikeska T and Craig J. DNA Methylation Biomarkers: Cancer and Beyond. Genes, 2014, 5 (3).
- Delpu Y, et al. DNA methylation and cancer diagnosis. Int J Mol Sci, 2013, 14(7): 15029-58.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
